Details of the Drug

General Information of Drug (ID: DM4O2Z7)

Drug Name

Cyclophosphamide

Synonyms

ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Central nervous system neoplasm	N.A.	Approved	[1]
Glioblastoma	2A00	Approved	[1]
Immunodeficiency	4A00-4A85	Approved	[1]
Inflammatory breast cancer	2C62	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[1]
Lymphoma	2A80-2A86	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Retinoblastoma	2D02.2	Investigative	[1]
Scleroderma	4A42	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

261.079

Logarithm of the Partition Coefficient (xlogp)

0.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 74% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [5]
Elimination: 6.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 12 hours [5]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.15051 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.87% [5]
Vd: The volume of distribution (Vd) of drug is 30-50 L []
Water Solubility: The ability of drug to dissolve in water is measured as 40 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiotoxicity	Not Available	TNNI2	OTGGZFSC	[7]
Haemolytic anaemia	Not Available	G6PD	OT300SMK	[7]
Porphyrin metabolism disorder	Not Available	UROD	OTPP4UH5	[7]
Pulmonary toxicity	Not Available	SOD1	OT39TA1L	[7]
Pulmonary toxicity	Not Available	GPX1	OTE2O72Q	[7]
Pulmonary toxicity	Not Available	GSR	OTM2TUYM	[7]
-----------


⏷ Show the Full List of 6 ADR Information of This Drug

Chemical Identifiers

Formula: C7H15Cl2N2O2P
IUPAC Name: N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
Canonical SMILES: C1CNP(=O)(OC1)N(CCCl)CCCl
InChI: InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
InChIKey: CMSMOCZEIVJLDB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2907
ChEBI ID: CHEBI:4027
CAS Number: 50-18-0
DrugBank ID: DB00531
TTD ID: D0CT9C
VARIDT ID: DR00425
INTEDE ID: DR0391
ACDINA ID: D00157

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[13]
Cytochrome P450 2B6 (CYP2B6)_{Main DME}	DEPKLMQ	CP2B6_HUMAN	Substrate	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[16]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[17]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[18]
Alanine aminotransferase 2 (GPT2)	OTS5VF7N	ALAT2_HUMAN	Gene/Protein Processing	[19]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Gene/Protein Processing	[20]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Drug Response	[21]
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Gene/Protein Processing	[20]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Gene/Protein Processing	[20]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[19]
Angiopoietin-1 (ANGPT1)	OTVZ1NG3	ANGP1_HUMAN	Gene/Protein Processing	[20]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[22]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cyclophosphamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
LEE011	DMMX75K	Moderate	Decreased metabolism of Cyclophosphamide caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
-----------

Coadministration of a Drug Treating the Disease Different from Cyclophosphamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Cyclophosphamide caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[24]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Repaglinide.	Acute diabete complication [5A2Y]	[25]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glibenclamide.	Acute diabete complication [5A2Y]	[25]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolazamide.	Acute diabete complication [5A2Y]	[25]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Nateglinide.	Acute diabete complication [5A2Y]	[25]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glipizide.	Acute diabete complication [5A2Y]	[25]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Cyclophosphamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Inotersen.	Amyloidosis [5D00]	[26]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Roflumilast.	Asthma [CA23]	[26]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[27]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Cyclophosphamide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
ABT-492	DMJFD2I	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[27]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Cyclophosphamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Atracurium.	Corneal disease [9A76-9A78]	[30]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Mivacurium.	Corneal disease [9A76-9A78]	[30]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Pancuronium.	Corneal disease [9A76-9A78]	[30]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Cyclophosphamide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[31]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Cyclophosphamide caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Cyclophosphamide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[33]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Cyclophosphamide caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Cyclophosphamide caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Cyclophosphamide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Cyclophosphamide caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Cyclophosphamide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Cyclophosphamide caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[38]
Amphotericin B	DMTAJQE	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Amphotericin B.	Fungal infection [1F29-1F2F]	[24]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Cyclophosphamide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Cyclophosphamide caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Cyclophosphamide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Cyclophosphamide caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[24]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[24]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Cyclophosphamide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[42]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Denosumab.	Low bone mass disorder [FB83]	[43]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Cyclophosphamide caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Cyclophosphamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[44]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Cyclophosphamide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[45]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Clofarabine.	Mature B-cell lymphoma [2A85]	[46]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Cyclophosphamide and Thalidomide.	Multiple myeloma [2A83]	[47]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Tecfidera.	Multiple sclerosis [8A40]	[48]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Siponimod.	Multiple sclerosis [8A40]	[24]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Fingolimod.	Multiple sclerosis [8A40]	[49]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Ocrelizumab.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Ozanimod.	Multiple sclerosis [8A40]	[26]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Cyclophosphamide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[51]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[52]
Prasugrel	DM7MT6E	Minor	Decreased metabolism of Cyclophosphamide caused by Prasugrel mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[26]
Modafinil	DMYILBE	Minor	Increased metabolism of Cyclophosphamide caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[53]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Cyclophosphamide caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[54]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Cyclophosphamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[55]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Cyclophosphamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[56]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Cyclophosphamide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[57]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Cyclophosphamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[58]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Cyclophosphamide caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[59]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Cyclophosphamide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[60]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[27]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Canakinumab.	Rheumatoid arthritis [FA20]	[61]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Rilonacept.	Rheumatoid arthritis [FA20]	[61]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Golimumab.	Rheumatoid arthritis [FA20]	[62]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Leflunomide.	Rheumatoid arthritis [FA20]	[41]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Cyclophosphamide when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[63]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Cyclophosphamide caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[26]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Cyclophosphamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[64]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Vecuronium.	Tonus and reflex abnormality [MB47]	[30]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Cisatracurium.	Tonus and reflex abnormality [MB47]	[30]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Rocuronium.	Tonus and reflex abnormality [MB47]	[30]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Cyclophosphamide and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[60]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Azathioprine.	Transplant rejection [NE84]	[65]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Cyclophosphamide and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[60]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[25]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[27]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Plazomicin.	Urinary tract infection [GC08]	[24]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Ganciclovir.	Virus infection [1A24-1D9Z]	[24]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Valganciclovir.	Virus infection [1A24-1D9Z]	[24]
-----------


⏷ Show the Full List of 80 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Sodium stearyl fumarate	E00545	23665634	lubricant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cyclophosphamide 25 mg capsule	25 mg	Oral Capsule	Oral
Cyclophosphamide 50 mg capsule	50 mg	Oral Capsule	Oral
Cyclophosphamide 25 mg tablet	25 mg	Oral Tablet	Oral
Cyclophosphamide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Cyclophosphamide FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
9	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
10	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
11	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
12	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
13	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
14	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
15	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
16	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
17	Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
18	Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
19	Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
20	Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
21	Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.
22	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
24	Cerner Multum, Inc. "Australian Product Information.".
25	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
28	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
29	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
30	Multum Information Services, Inc. Expert Review Panel.
31	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32	Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
33	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
34	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
35	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
36	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
37	Garattini S, Spreafico F "Some examples of interactions between drugs in cancer chemotherapy." Antibiot Chemother 23 (1978): 283-94. [PMID: 348085]
38	Chang TK, Yu L, Maurel P, Waxman DJ "Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines." Cancer Res 57 (1997): 1946-54. [PMID: 9157990]
39	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
40	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
41	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
42	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
43	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
44	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
45	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
47	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
48	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
49	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
50	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
51	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
52	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
53	Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
54	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
55	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
56	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
57	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
58	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
59	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
60	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
61	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
62	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
63	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
64	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
65	Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM "Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine." Q J Med 67 (1988): 309-17. [PMID: 3060893]